MiR-206 suppresses proliferation and epithelial-mesenchymal transition of renal cell carcinoma by inhibiting CDK6 expression


Increasing evidence indicates that miRNAs are involved in tumorigenesis of human renal cell carcinoma (RCC). However, the role of miR-206 is still unknown. This study aimed to investigate the possible mechanism of miR-206 in progression of RCC. Here, compared with adjacent normal renal tissues and HK-2 cells, miR-206 level was markedly decreased, whereas CDK6 level was obviously increased in RCC tissues and cell lines. MiR-206 was inversely associated with lymph node metastasis and TNM stage, and acted as an independent prognostic factor in RCC. MiR-206 effectively caused apoptosis and cell cycle arrest at G0/G1 phase, and affected the growth of xenograft tumor of nude mice. MiR-206 also inhibited migration and invasion of RCC cells by modulating the expressions of EMT-related genes. Dual-luciferase assay demonstrated CDK6 was a direct target of miR-206. CDK6 silencing aggravated the inhibition effects of miR-206. In conclusion, miR-206 suppresses proliferation and EMT of RCC by inhibiting CDK6 expression. The miR-206/CDK6 axis may provide a novel insight into tumorigenesis of RCC.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. 1.

    Meyer AR, Carducci MA, Denmeade SR, et al. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med. 2019;33(8):617–23.

    PubMed  Article  Google Scholar 

  2. 2.

    Patel HD, Puligandla M, Shuch BM, et al. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019;15(15):1683–95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Tabei T, Nakaigawa N, Kaneta T, et al. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC Cancer. 2019;19(1):298.

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Todo M, Shirotake S, Nishimoto K, et al. Usefulness of implementing comprehensive pharmaceutical care for metastatic renal cell carcinoma outpatients treated with pazopanib. Anticancer Res. 2019;39(2):999–1004.

    PubMed  Article  Google Scholar 

  5. 5.

    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.

    CAS  Article  Google Scholar 

  7. 7.

    Becam I, Rafel N, Hong X, et al. Notch-mediated repression of bantam miRNA contributes to boundary formation in the Drosophila wing. Development. 2011;138:3781–9.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Berindan-Neagoe I, Monroig PC, Pasculli B, et al. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64:311–36.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Wang Y, Tian Y. miR-206 inhibits cell proliferation, migration, and invasion by targeting BAG3 in human cervical cancer. Oncol Res. 2018;26(6):923–31.

    PubMed  Article  Google Scholar 

  11. 11.

    Hao W, Luo W, Bai M, et al. MicroRNA-206 inhibited the progression of glioblastoma through BCL-2. J Mol Neurosci. 2016;60(4):531–8.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Jia KG, Feng G, Tong YS, et al. miR-206 regulates non-small cell lung cancer cell aerobic glycolysis by targeting hexokinase 2. J Biochem. 2019;167(4):365–70.

    Article  Google Scholar 

  13. 13.

    Wang Y, Tai Q, Zhang J, et al. MiRNA-206 inhibits hepatocellular carcinoma cell proliferation and migration but promotes apoptosis by modulating cMET expression. Acta Biochim Biophys Sin (Shanghai). 2019;51(3):243–53.

    CAS  Article  Google Scholar 

  14. 14.

    Dai C, Xie Y, Zhuang X, et al. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. Biomed Pharmacother. 2018;104:763–70.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Ni Z, Shang X, Tang G, et al. Expression of miR-206 in human knee articular chondrocytes and effects of miR-206 on proliferation and apoptosis of articular chondrocytes. Am J Med Sci. 2018;355(3):240–6.

    PubMed  Article  Google Scholar 

  16. 16.

    Pan BL, Tong ZW, Wu L, et al. Effects of microRNA-206 on osteosarcoma cell proliferation, apoptosis, migration and invasion by targeting ANXA2 through the AKT signaling pathway. Cell Physiol Biochem. 2018;45(4):1410–22.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Vergara D, Simeone P, Damato M, et al. The cancer microbiota: EMT and inflammation as shared molecular mechanisms associated with plasticity and progression. J Oncol. 2019;2019:1253727.

    PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Boros É, Nagy I. The role of MicroRNAs upon epithelial-to-mesenchymal transition in inflammatory bowel disease. Cells. 2019;8(11):E1461.

    PubMed  Article  Google Scholar 

  19. 19.

    Jiao D, Chen J, Li Y, et al. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. J Cell Mol Med. 2018;22(7):3526–36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Yin K, Yin W, Wang Y, et al. MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells. Oncotarget. 2016;7(17):24537–48.

    PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Wang LS, Chen SJ, Zhang JF, et al. Anti-proliferative potential of glucosamine in renal cancer cells via inducing cell cycle arrest at G0/G1 phase. BMC Urol. 2017;17(1):38.

    PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013;33(8):2997–3004.

    CAS  PubMed  Google Scholar 

  23. 23.

    Lin JA, Fang SU, Su CL, et al. Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy. Urol Oncol. 2014;32(1):29.e1–11.

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Junke Ge.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The human study was approved by the Ethics Committee of Jinan Central Hospital Affiliated to Shandong First Medical University. All the RCC samples were collected with written informed consent in accordance with the Declaration of Helsinki. All experimental animal procedures in this study conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by the Institutional Animal Care and Use Committee of Jinan Central Hospital Affiliated to Shandong First Medical University.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Guo, Z., Jia, H. & Ge, J. MiR-206 suppresses proliferation and epithelial-mesenchymal transition of renal cell carcinoma by inhibiting CDK6 expression. Human Cell 33, 750–758 (2020). https://doi.org/10.1007/s13577-020-00355-5

Download citation


  • MiR-206
  • CDK6
  • RCC
  • Suppression